From: Hepcidin Expression in the Liver: Relatively Low Level in Patients with Chronic Hepatitis C
Characteristic | Hepcidin mRNA level | Statistics | |||
---|---|---|---|---|---|
n | Mean ± SD | Median | r | P | |
Age, y | Â | Â | Â | 0.003 | 0.9764 |
Sex | Â | Â | Â | Â | 0.0012a |
Male | 73 | 10,900 ± 13,100 | 6590 |  |  |
Female | 59 | 5820 ± 10,700 | 2600 |  |  |
Virus infection | Â | Â | Â | Â | Â |
Male | Â | Â | Â | Â | Â |
HCV+ | 33 | 9120 ± 7660 | 6650 |  |  |
HBV+ | 23 | 11,800 ± 16,100 | 2600 |  |  |
HCV−HBV− |  |  |  |  | 0.0611b |
Non-iron overload | 9 | 7750 ± 5320 | 6590 |  |  |
Iron overload | 8 | 19,600 ± 23,000 | 15,800 |  |  |
Female | Â | Â | Â | Â | Â |
HCV+ | 23 | 5890 ± 7900 | 3690 |  |  |
HBV+ | 11 | 3000 ± 2190 | 2360 |  |  |
HCV−HBV− |  |  |  |  | 0.0724b |
Non-iron overload | 15 | 1300 ± 1030 | 814.5 |  |  |
Iron overload | 10 | 15,500 ± 20,800 | 6485 |  |  |
Total | Â | Â | Â | Â | Â |
HCV+ | 56 | 7790 ± 7850 | 5730 |  |  |
HBV+ | 34 | 8950 ± 13,900 | 3290 |  |  |
HCV−HBV− |  |  |  |  | 0.7733b |
Non-iron overload | 24 | 3720 ± 4550 | 1650 |  |  |
Iron overload | 18 | 17,300 ± 21,200 | 6770 |  |  |
ALT, IU/L | Â | Â | Â | 0.281 | 0.0013 |
AST, IU/L | Â | Â | Â | 0.249 | 0.0043 |
Serum albumin, g/dL |  |  |  | −0.036 | 0.7844 |
Bilirubin, mg/dL | Â | Â | Â | 0.239 | 0.0065 |
Hyaluronic acid, ng/mL | Â | Â | Â | 0.145 | 0.0968 |
RBC, ×104/mm3 |  |  |  | 0.171 | 0.0510 |
Hemoglobin, g/L | Â | Â | Â | 0.235 | 0.0073 |
Hematocrit, % | Â | Â | Â | 0.160 | 0.0675 |
Platelets, × 104/mm3 |  |  |  | −0.174 | 0.0465 |
Serum iron, µg/dL |  |  |  | 0.283 | 0.0012 |
Transferrin saturation, % | Â | Â | Â | 0.360 | <0.0001 |
Serum ferritin, ng/mL | Â | Â | Â | 0.832 | <0.0001 |
Liver histology | Â | Â | Â | Â | Â |
Inflammatory activity, 0/1/2/3c | Â | Â | Â | 0.073 | 0.4011 |
Fibrosis staging, 0/1/2/3/4d | Â | Â | Â | 0.031 | 0.7209 |
TISe | Â | Â | Â | 0.457 | <0.0001 |